Latest News and Press Releases

Heat-triggered release mechanism unequivocally confirmedFavorable safety profile with good tolerability Signs of encouraging clinical activity in heavily pre-treated patients including meaningful...

ODD granted for the treatment of soft tissue sarcomas (STS)Thermosome adds 4 patents to its growing patent estate Munich, Germany – May 12, 2025 – Thermosome, a drug development company focused on...

Dublin, Feb. 10, 2025 (GLOBE NEWSWIRE) -- The "Doxorubicin - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Doxorubicin was valued at...

Dublin, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global liposomal...

Independent Data Safety Monitoring Board declared dose level 2 as safe and recommended escalation to final dose level 3 Munich, Germany – December 4, 2024 – Thermosome, a drug development company...

THE001 safe and well tolerated in first two dose level, demonstrating encouraging signs of clinical activityData presented at The Connective Tissue Oncology Society (CTOS) Annual Meeting 2024 Munich,...

Dublin, Nov. 07, 2024 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Report and Forecast 2024-2032" report has been added to ResearchAndMarkets.com's offering.The global liposomal...

Dublin, Sept. 30, 2024 (GLOBE NEWSWIRE) -- The "Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By...

Dublin, Sept. 23, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin Market Size, Share & Trends Analysis Report By Drug Formulation (Lyophilized Powder, Doxorubicin Injection), By Application, By...

Dublin, April 05, 2024 (GLOBE NEWSWIRE) -- The "Doxorubicin - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Doxorubicin Market to Reach $1.7...